ARTICLE | Emerging Company Profile
TargED: targeting thrombotic disorders directly at clotting sites
Dutch start-up with about €40M in funding will advance fusion protein targeting von Willebrand factor for two indications
February 22, 2022 10:44 PM UTC
A European VC syndicate has backed TargED, a Dutch start-up advancing a fusion protein designed to address thrombotic disorders by delivering an enzyme directly to clotting sites.
Formed in 2020 around work at University Medical Center Utrecht, TargED Biopharmaceuticals N.V. is led by co-founder and CEO Kristof Vercruysse, a former head of clinical development at Ablynx N.V. during its development of anti-thrombotic Cablivi caplacizumab-yhdp...